{"id":"https://openalex.org/W2532056566","doi":"https://doi.org/10.3233/jad-160701","title":"AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer\u2019s Disease","display_name":"AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer\u2019s Disease","alternate_titles":[],"publication_year":2016,"publication_date":"2016-10-19","ids":{"openalex":"https://openalex.org/W2532056566","doi":"https://doi.org/10.3233/jad-160701","mag":"2532056566","pmid":"https://pubmed.ncbi.nlm.nih.gov/27767991"},"language":"en","primary_location":{"id":"doi:10.3233/jad-160701","doi":"https://doi.org/10.3233/jad-160701","is_oa":false,"landing_page_url":"https://doi.org/10.3233/jad-160701","pdf_url":null,"source":{"id":"https://openalex.org/S25155249","display_name":"Journal of Alzheimer s Disease","issn_l":"1387-2877","issn":["1387-2877","1875-8908"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318577","host_organization_name":"IOS Press","host_organization_lineage":["https://openalex.org/P4310318577"],"host_organization_lineage_names":["IOS Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer\u2019s Disease","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2532056566"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063415568","display_name":"Gvido Cebers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gvido Cebers","raw_affiliation_strings":["AstraZeneca, Neuroscience, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Neuroscience, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103079586","display_name":"Robert Alexander","orcid":"https://orcid.org/0000-0002-6889-2952","observed_orcids":["https://orcid.org/0000-0002-6889-2952"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert C. Alexander","raw_affiliation_strings":["AstraZeneca, Neuroscience, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Neuroscience, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058317902","display_name":"Samantha Budd Haeberlein","orcid":"https://orcid.org/0000-0002-4824-646X","observed_orcids":["https://orcid.org/0000-0002-4824-646X"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Samantha Budd Haeberlein","raw_affiliation_strings":["AstraZeneca, Neuroscience, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Neuroscience, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114155555","display_name":"David Han","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David Han","raw_affiliation_strings":["Early Phase Clinical Unit, USA","PAREXEL, Early Phase Clinical Unit, Glendale, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Phase Clinical Unit, USA","institution_ids":[]},{"raw_affiliation_string":"PAREXEL, Early Phase Clinical Unit, Glendale, CA, USA","institution_ids":["https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033179964","display_name":"Ronald Goldwater","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802898841","display_name":"MedStar Harbor Hospital","ror":"https://ror.org/05mdb5j94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802898841"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ronald Goldwater","raw_affiliation_strings":["Harbor Hospital, USA","PAREXEL, Clinical Pharmacology Research Unit, Harbor Hospital, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harbor Hospital, USA","institution_ids":[]},{"raw_affiliation_string":"PAREXEL, Clinical Pharmacology Research Unit, Harbor Hospital, Baltimore, MD, USA","institution_ids":["https://openalex.org/I2802898841"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009531510","display_name":"Larry Ereshefsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Larry Ereshefsky","raw_affiliation_strings":["Early Phase Clinical Unit, USA","PAREXEL, Early Phase Clinical Unit, Glendale, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Phase Clinical Unit, USA","institution_ids":[]},{"raw_affiliation_string":"PAREXEL, Early Phase Clinical Unit, Glendale, CA, USA","institution_ids":["https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104074178","display_name":"Tina Olsson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tina Olsson","raw_affiliation_strings":["AstraZeneca, Neuroscience, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Neuroscience, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065200734","display_name":"Naidong Ye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Naidong Ye","raw_affiliation_strings":["AstraZeneca, Neuroscience, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Neuroscience, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109115059","display_name":"Laura B. Rosen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Laura Rosen","raw_affiliation_strings":["AstraZeneca, Neuroscience, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Neuroscience, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030340195","display_name":"Muir Russell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Muir Russell","raw_affiliation_strings":["AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Alderley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Alderley Park, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059007001","display_name":"Justine Maltby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Justine Maltby","raw_affiliation_strings":["AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Alderley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Protein Biomarkers, Personalised Healthcare and Biomarkers, Alderley Park, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013407044","display_name":"Susanna Eketj\u00e4ll","orcid":"https://orcid.org/0000-0003-2165-1251","observed_orcids":["https://orcid.org/0000-0003-2165-1251"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210105493","display_name":"Integrated Cardio Metabolic Centre","ror":"https://ror.org/01pgex273","country_code":"SE","type":"facility","lineage":["https://openalex.org/I105036370","https://openalex.org/I28166907","https://openalex.org/I4210105493","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Susanna Eketj\u00e4ll","raw_affiliation_strings":["Karolinska Institutet, Sweden","AstraZeneca Integrated Cardio Metabolic Centre, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, Karolinska Institutet, Solna, Sweden","E-mail:","Fax: +46 8 31 11 01"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karolinska Institutet, Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"AstraZeneca Integrated Cardio Metabolic Centre, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, Karolinska Institutet, Solna, Sweden","institution_ids":["https://openalex.org/I28166907","https://openalex.org/I4210105493"]},{"raw_affiliation_string":"E-mail:","institution_ids":[]},{"raw_affiliation_string":"Fax: +46 8 31 11 01","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091559601","display_name":"Alan R. Kugler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alan R. Kugler","raw_affiliation_strings":["AstraZeneca, Neuroscience, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Neuroscience, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5013407044"],"corresponding_institution_ids":["https://openalex.org/I28166907","https://openalex.org/I4210105493"],"apc_list":null,"apc_paid":null,"fwci":4.918,"has_fulltext":false,"cited_by_count":104,"citation_normalized_percentile":{"value":0.96953889,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"55","issue":"3","first_page":"1039","last_page":"1053"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7834287881851196},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7129632234573364},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6739144921302795},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5860148668289185},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.46244651079177856},{"id":"https://openalex.org/C2779651940","wikidata":"https://www.wikidata.org/wiki/Q54196","display_name":"Cerebrospinal fluid","level":2,"score":0.4515692889690399},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4439653158187866},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4362962245941162},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3880186378955841}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005502","descriptor_name":"Food","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009460","descriptor_name":"Neurologic Examination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000134","qualifier_name":"cerebrospinal fluid","is_major_topic":false},{"descriptor_ui":"D013141","descriptor_name":"Spiro Compounds","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013141","descriptor_name":"Spiro Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000134","qualifier_name":"cerebrospinal fluid","is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3233/jad-160701","doi":"https://doi.org/10.3233/jad-160701","is_oa":false,"landing_page_url":"https://doi.org/10.3233/jad-160701","pdf_url":null,"source":{"id":"https://openalex.org/S25155249","display_name":"Journal of Alzheimer s Disease","issn_l":"1387-2877","issn":["1387-2877","1875-8908"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318577","host_organization_name":"IOS Press","host_organization_lineage":["https://openalex.org/P4310318577"],"host_organization_lineage_names":["IOS Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer\u2019s Disease","raw_type":"journal-article"},{"id":"pmid:27767991","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27767991","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer's disease : JAD","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W1512916808","https://openalex.org/W1556033735","https://openalex.org/W1847168837","https://openalex.org/W1921787609","https://openalex.org/W1929267935","https://openalex.org/W1967778108","https://openalex.org/W1969810313","https://openalex.org/W1980906872","https://openalex.org/W1993426606","https://openalex.org/W1995051494","https://openalex.org/W2000536660","https://openalex.org/W2015484447","https://openalex.org/W2019461415","https://openalex.org/W2030641075","https://openalex.org/W2036288989","https://openalex.org/W2041573170","https://openalex.org/W2056414888","https://openalex.org/W2058723245","https://openalex.org/W2059030964","https://openalex.org/W2079749054","https://openalex.org/W2090150925","https://openalex.org/W2096410114","https://openalex.org/W2098035383","https://openalex.org/W2105631420","https://openalex.org/W2112329611","https://openalex.org/W2115017507","https://openalex.org/W2116774394","https://openalex.org/W2121566293","https://openalex.org/W2124074440","https://openalex.org/W2129495914","https://openalex.org/W2139818289","https://openalex.org/W2154755614","https://openalex.org/W2155237226","https://openalex.org/W2166109990","https://openalex.org/W2169356930","https://openalex.org/W2245231029","https://openalex.org/W2258663952","https://openalex.org/W2473342350","https://openalex.org/W2949891624","https://openalex.org/W3171418018","https://openalex.org/W4285719527","https://openalex.org/W7074234824"],"related_works":["https://openalex.org/W2539016063","https://openalex.org/W2536505568","https://openalex.org/W1512916808","https://openalex.org/W2258663952","https://openalex.org/W2060598171","https://openalex.org/W2108087296","https://openalex.org/W2167272696","https://openalex.org/W2123191001","https://openalex.org/W1976333571","https://openalex.org/W2626081108"],"abstract_inverted_index":{"AZD3293":[0,101,220,246],"(LY3314814)":[1],"is":[2,221],"a":[3,32,43,51,153,216,234],"promising":[4],"new":[5],"potentially":[6],"disease-modifying":[7],"BACE1":[8,224],"(\u03b2-secretase)":[9],"inhibitor":[10,225],"in":[11,73,88,158,184],"Phase":[12,28,242],"III":[13,243],"clinical":[14],"development":[15],"for":[16,168,226],"the":[17,25,108,140,174,222],"treatment":[18],"of":[19,39,59,126,134,150,230,245],"Alzheimer's":[20,94],"disease.":[21],"Reported":[22],"here":[23],"are":[24,252],"first":[26],"two":[27],"I":[29],"studies:":[30],"(1)":[31],"single":[33,148],"ascending":[34,54],"dose":[35,55,145,176],"study":[36,56],"evaluating":[37,57],"doses":[38,58,110,121,149],"1-750":[40],"mg":[41,63,69,86,144,189,201],"with":[42,90,165,215,233],"food-effect":[44],"component":[45],"(n":[46],"=":[47,79,99],"72),":[48],"and":[49,81,131,162,190,195,202,249],"(2)":[50],"2-week":[52],"multiple":[53,120,180],"15":[60,141,188,200],"or":[61,67,84],"50":[62],"once":[64,70],"daily":[65],"(QD)":[66],"70":[68],"weekly":[71],"(QW)":[72],"elderly":[74],"subjects":[75],"(Part":[76,96,122],"1,":[77],"n":[78,98],"31),":[80],"15,":[82],"50,":[83],"150":[85,143],"QD":[87],"patients":[89],"mild":[91],"to":[92,107,128,136,142,170],"moderate":[93],"disease":[95],"2,":[97],"16).":[100],"was":[102,156],"generally":[103],"well":[104],"tolerated":[105],"up":[106,169],"highest":[109,175],"given.":[111],"No":[112],"notable":[113],"food":[114],"effects":[115],"were":[116,124,209],"observed.":[117],"PK":[118],"following":[119],"2)":[123],"tmax":[125],"1":[127],"3":[129,171],"h":[130,138],"mean":[132,159],"t1/2":[133],"16":[135],"21":[137],"across":[139],"range.":[146],"For":[147],"\u22655":[151],"mg,":[152],"\u226570%":[154],"reduction":[155],"observed":[157],"plasma":[160,185,231],"A\u03b240":[161],"A\u03b242":[163],"concentrations,":[164],"prolonged":[166,212,228],"suppression":[167,213,229],"weeks":[172],"at":[173,187,192,199,204],"level":[177],"studied.":[178],"Following":[179],"doses,":[181],"robust":[182],"reductions":[183],"(\u226564%":[186],"\u226578%":[191],"\u226550":[193,205],"mg)":[194,206],"cerebrospinal":[196],"fluid":[197],"(\u226551%":[198],"\u226576%":[203],"A\u03b2":[207,232],"peptides":[208],"seen,":[210],"including":[211],"even":[214],"QW":[217,235],"dosing":[218,236],"regimen.":[219],"only":[223],"which":[227],"schedule":[237],"has":[238],"been":[239],"reported.":[240],"Two":[241],"studies":[244],"(AMARANTH,":[247],"NCT02245737;":[248],"DAYBREAK-ALZ,":[250],"NCT02783573)":[251],"now":[253],"ongoing.":[254]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2532056566","counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":17},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":18},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-10-28T00:00:00"}
